Area of research
Immunology · Dermatology
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Spondyloarthritis Studies and Treatments, and Asthma and respiratory diseases.
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.
A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study.
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials.
Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months.
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity.
GRAPPA 2025 Collaborative Research Network Meeting: Difficult-to-Treat Psoriatic Arthritis and Future Strategies for Curing Psoriasis.
Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R.
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.
Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient‐Reported Outcomes in a Randomized Trial
Subclinical atherosclerosis is increased in moderate-to-severe atopic dermatitis.
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis.
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab.
A Dual-Action Mechanism to Prevent OX40 Signaling: The Structural Basis for the Differentiated Antagonist STAR-0310
Bimekizumab as-needed dosing in patients with psoriasis: a case series.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Targeting <scp>IL</scp>‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (<scp>POETYK PSO</scp>‐1 and <scp>PSO</scp>‐2)
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.